XKRX
003060
Market cap15mUSD
Oct 08, Last price
1,544.00KRW
1D
0.26%
1Q
-25.95%
Jan 2017
-92.25%
Name
Aprogen Biologics Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aprogen Biologics, Inc. specializes in the production and distribution of pharmaceutical goods. The company's activities are structured across two main segments: Pharmaceutical and Bio. Its Pharmaceutical division supplies synthetic medicines, encompassing treatments for the circulatory, central nervous, and digestive systems, alongside antibiotics. Concurrently, the Bio division is dedicated to developing and manufacturing biopharmaceuticals. Aprogen Biologics was established on December 3, 1960, and its corporate headquarters are situated in Seoul, South Korea.
Key people
Jeong Chul Kim
Co-Chief Executive Officer, Director · since 2023
Jong Su Kang
Managing Director
An Su Kim
Managing Director
Gi Mun Hong
Internal Auditor · since 2025
Min Cheol Jung
Internal Auditor
Seong Ho Kang
Assistant Managing Director
Seon Ju Kang
Assistant Managing Director · since 2021
Oh Seong Nah
Assistant Managing Director
Yeong Suk Yum
Assistant Managing Director
Assistant Managing Director
Co-Chief Executive Officer, Director · since 2023
Dong Cheol Shin
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||